Friday, September 29, 2023


Biotechnology News Magazine


Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine

Enesi Pharma announced that it has successfully developed an ImplaVax®-enabled, solid-dose recombinant H7N9 pandemic influenza vaccine and delivered proof-of-concept results in validated preclinical models.

ECI Pharmaceuticals LLC Enters into Exclusive U.S. Distribution Agreement for Ibuprofen Prescription Strength Tablets and Folic Acid Prescription Strength Tablets

According to IQVIA data for the 12 months ended December 2020, total U.S. generic sales of Ibuprofen tablets 400 mg, 600 mg, 800 mg was approximately $110 million.

AIkido Pharma Notes Advancement in Radiopharmaceutical Research

Alkido Pharma notes the report provides strong indications for analogous success in similar technology the Company is helping to develop. 

Kintor Pharmaceutical and Visum Announced Strategic Partnership to Expand Proxalutamide Manufacturing

At present, Kintor Pharmaceutical is completing the Brazilian clinical trials of proxalutamide for treatment of male and female COVID-19 patients with mild or moderate symptoms and COVID-19 patients with severe symptoms.

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

Under the three-year collaboration, Artios and Novartis will perform target discovery and validation, and Novartis will select up to three exclusive DDR targets, and receive worldwide rights on these targets to be utilized with its RLT’s.

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

Based on this data, the Company plans to commence a Phase 3 clinical trial by the end of April 2021, subject to regulatory approval.